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Abstract
Background: Cyclic vomiting syndrome (CVS), defined by recurrent stereotypical episodes of nausea and vomiting,
is a relatively-common disabling and historically difficult-to-treat condition associated with migraine headache and
mitochondrial dysfunction. Limited data suggests that the anti-migraine therapies amitriptyline and
cyproheptadine, and the mitochondrial-targeted cofactors co-enzyme Q10 and L-carnitine, have efficacy in episode
prophylaxis.
Methods: A retrospective chart review of 42 patients seen by one clinician that met established CVS diagnostic
criteria revealed 30 cases with available outcome data. Participants were treated on a loose protocol consisting of
fasting avoidance, co-enzyme Q10 and L-carnitine, with the addition of amitriptyline (or cyproheptadine in those <
5 years) in refractory cases. Blood level monitoring of the therapeutic agents featured prominently in management.
Results: Vomiting episodes resolved in 23 cases, and improved by > 75% and > 50% in three and one additional
case respectively. Among the three treatment failures, two could not tolerate amitriptyline (as was also the case in
the child with only > 50% efficacy) and one had multiple congenital gastrointestinal anomalies. Excluding the latter
case, substantial efficacy (> 75% response) was 26/29 at the start of treatment, and 26/26 in those able to tolerate
the regiment, including high dosages of amitriptyline.
Conclusion: Our data suggest that a protocol consisting of mitochondrial-targeted cofactors (co-enzyme Q10 and
L-carnitine) plus amitriptyline (or possibly cyproheptadine in preschoolers) coupled with blood level monitoring is
highly effective in the prevention of vomiting episodes.
Background
Cyclic vomiting syndrome (CVS) is characterized by
recurrent identical episodes of nausea and vomiting,
with the absence of these symptoms between episodes
[1]. CVS is likely common, being present in about 2% of
Scottish [2] and Western Australian [3] school children.
Prior to the advent of successful therapy, CVS was a dis-
abling condition as episodes are generally severe, usually
last for days, and often require intravenous fluid therapy
for dehydration [1]. Frequent and prolonged school or
work absences lead to academic or work disability. CVS
can pose a challenge for clinicians to manage, and it is
common for patients to seek help from multiple practi-
tioners because of continued vomiting episodes.
Although the etiology is unknown, substantial parallels
with migraine headache [4] have prompted therapeutic
trials with anti-migraine therapies. Amitriptyline (Ela-
vil
®), a tricyclic “antidepressant” frequently used to treat
migraine, is the most widely prescribed prophylactic
medication used for the treatment of CVS, with
response rates varying from 52-73% in open-label and
subject recall-based studies in children and adults
[reviewed in 5]. In a recent consensus statement, ami-
triptyline was recommended as the first-line treatment
choice for CVS prophylaxis in children and adolescents
age 5 years and older, while cyproheptadine is recom-
mended in younger children [1].
Mitochondrial dysfunction is hypothesized to be a fac-
tor in the pathogenesis of both CVS and migraine
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enzymology, disease-associated mitochondrial DNA
(mtDNA) sequence variants, and preferential maternal
inheritance [reviewed in 5]. Physicians and other health
care providers are increasingly recommending co-
enzyme Q10, also known as ubiquinone, a commonly-
used dietary supplement that is widely available in retail
settings, for the treatment of a wide variety of condi-
tions, including mitochondrial dysfunction. Co-enzyme
Q10 serves as the electron shuttle between complexes 1
or 2 and complex 3 of the mitochondrial respiratory
chain [6]. In migraine, a randomized control trial
demonstrated therapeutic efficacy [7]. Recently, the use
of co-enzyme Q10 has been gaining in popularity
among CVS patient groups. A recent subject recall-
based study in CVS suggested equivalent efficacy of co-
enzyme Q10 and amitriptyline (~70%), but with superior
tolerability of co-enzyme Q10 [5]. There was inadequate
data to assess response to combination therapy with
both agents.
L-carnitine is also a naturally-occurring dietary sup-
plement that is frequently used in the treatment of
mitochondrial dysfunction [6]. L-carnitine is a shuttle of
long-chain fatty acids across the inner mitochondrial
m e m b r a n ea n dt h u si sr e q u i r e df o rf a to x i d a t i o n .I n
addition, L-carnitine has a “detoxifying” role in shuttling
accumulated intermediates of metabolism out of
impaired mitochondria. One case series [8] demon-
strated efficacy of L-carnitine in CVS prophylaxis.
In the author’s clinical experience, episodes of nausea
and vomiting diminish markedly in the vast majority of
CVS patients treated with a protocol consisting of fasting
avoidance, co-enzyme Q10, and L-carnitine, with the addi-
tion of amitriptyline or cyproheptidine in refractory parti-
cipants over and under the age of five years, respectively.
One essential aspect of this protocol is dosing based on
blood levels. The current study is a retrospective chart
review of the 42 CVS patients evaluated over a two-year
period by the author to evaluate therapeutic responses.
Methods
A computer-generated report of all clinic patients seen
by the author during the two-year period from 7/1/06
to 6/30/08 was reviewed for ICD 9 codes used by the
author for CVS patients, including 536.2 and 277.87. A
medical record review was performed on all cases so
identified. Patients were included as participants in this
study if given a diagnosis of CVS by the author based
on fulfilling both the NASPGHAN [1] and Rome III [9]
criteria. All participants are unrelated. All records were
reviewed up until 6/30/10, allowing for a two-year fol-
low-up period to access medium-term treatment
responses. This study was approved by the Children’s
Hospital Los Angeles Institutional Review Board.
Participants were treated on a clinical basis, and not as
part of a prospective study; however, treatment during
this period was standardized as based on prior clinical
experience and the literature [1]:
￿ Dietary: All subjects were advised to make dietary
changes [1], including the “3+3 diet” (3 meals and 3
snacks a day including between meals and at bed-
time), and the avoidance of fasting.
￿ Co-enzyme Q10: Participants were treated with co-
enzyme Q10 (ubiquinone) in liquid or gel capsule
form (from a variety of brands) at a starting dose of
10 mg/kg/day, or 200 mg, divided twice a day,
whichever is smaller.
￿ L-carnitine: Participants were treated with Carnitor
brand or generics at a starting dose of 100 mg/kg/
day divided BID, or 2 grams twice a day, whichever
is smaller. A small minority of families, all with
untreated free carnitine blood levels > 30 micromo-
lar, were not treated.
￿ Amitriptyline: Participants age 5 years and over
with continued vomiting episodes despite the above
therapies were treated at a starting dose of 0.5 mg/
kg/day given at night An EKG was performed look-
ing at the QTc interval prior to and a few weeks fol-
lowing starting treatment.
￿ Cyproheptadine: Participants under the age of 5
years with continued vomiting episodes despite the
above therapies were treated at a starting dose of
0.25 mg/kg/day divided twice a day.
￿ Topiramate: Two participants who were refractory
to all of the above measures were started on 25 mg
of topiramate twice a day.
Dosages were increased every one to a few months
until one of the following occurred:
￿ Resolution of vomiting episodes
￿ Intolerable side effects that failed a reduction in
dosage followed by a slow dosage increase
￿ The following maximum was reached (empirically-
derived):
ο Co-enzyme Q10: blood level > 3.0 mg/L
ο L-carnitine: free carnitine blood level > 40
micromolar
ο Amitriptyline*: amitriptyline + nortriptyline
blood level > 150 ng/ml
ο Cyproheptadine: Dosage of 0.5 mg/kg/day
ο Topiramate Dosage of 200 mg twice a day (in
adolescents and adults)
*Blood levels were not routinely monitored for
dosages < 1 mg/kg/day as they were uniformly low in
the authors’ prior experience.
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sode frequency and episode duration. The efficacy cate-
gory was determined by the percent improvement in the
parameter demonstrating the greatest response at the
time of the most-recent clinic visit prior to 6-30-10:
￿ Resolution (episodes resolved, allowing for one epi-
sode a year with an obvious trigger, usually a febrile
infection).
￿ > 75% improvement (between 75-100% response in
at least one episode parameter).
￿ > 50-75% improvement (between 50-75% response
in at least one episode parameter)
￿ Treatment failure (< 50% improvement in both
parameters)
Results
A total of 42 participants met the study criteria. Age at
the time of chart review varied from 3 to 26 years, with
am e d i a no f1 2y e a r s .T h ea g eo ft h eo n s e to fv o m i t i n g
episodes was 1 week to 15 years, with a median of 4
years. The female:male ratio was 2.2:1 (29 females and
13 males). The race/ethnicity was 28 (67%) Caucasians,
11 (26%) Hispanics, 2 (5%) African-Americans, and 1
(2%) Native-American. Several co-morbid, predomi-
nantly-"functional”, conditions were common, ranging
from zero (in two adults) to 16 per participant, with a
median of 5.5 co-morbid conditions (Table 1).
The inheritance pattern as estimated by Quantitative
Pedigree Analysis [10] in the 35 cases with available
data was 21 (60%) participants with probable maternal
inheritance, 4 (11%) indeterminate, and 10 (29%) with
probable non-maternal inheritance.
Nine participants were excluded from outcome ana-
lyses because they were seen in clinic only once or
twice, and no follow-up data was available to determine
their response to therapy, including five of the 10 adults
(age > 18 years), but only 4 of the 32 children (P =
0.02). Two additional children were excluded because
CVS resolved prior to starting therapy. One additional
case was excluded because the parents declined prophy-
lactic therapy and chose to continue to abort episodes
with lorazepam and diphenhydramine.
Records in the remaining 30 subjects were queried for
data related to treatment response (Table 2). This
included three participants over the age of 18 years who
were included in the study as they are of ages com-
monly treated by pediatricians, and the physiology of
youth in their early to mid 20s is similar to that of
adolescents.
The treatment protocol failed in three cases, and was
sub-optimal (50-75% response) in another case. In one
of the treatment failure cases, episodes completely
resolved for several months on amitriptyline alone.
Unfortunately, a prolonged QTc interval was noted,
which resolved on discontinuation without adverse
events. Episodes then returned, but further therapy and
evaluation were complicated by severe non-compliance.
Two participants on amitriptyline, co-enzyme Q10, and
carnitine had tolerance issues with amitriptyline. One of
them (also labeled as treatment failure) demonstrated
good efficacy, yet amitriptyline was discontinued
because of narcolepsy, and episodes returned. In the
other case (labeled as sub-optimal), behavioral and emo-
tional effects have limited treatment to a sub-therapeutic
amitriptyline level associated with only partial efficacy.
In the final case of treatment failure, no improvement
was noted on the same three treatments, as well as with
the further addition of cyproheptadine. This latter infant
has multiple malformations, including esophageal atre-
sia, tracheoesophageal fistula, imperforate anus, and a
tethered spinal cord, as part of VATER association, and
thus was excluded from further data analyses.
Six participants reported side effects with amitripty-
line. In addition to the three cases discussed above in
which side effects necessitated treatment discontinuation
or reduction, in three other participants side effects
Table 1 Chronic co-morbidities at 10% or greater
prevalence among the 42 participants
Category or Condition Number Percent
Chronic pain syndromes (any) 31 74%
Extremity pain 17 40%
Headache (all but one with migraine) 16 38%
Abdomen 15 36%
Complex regional pain syndrome 5 12%
Gastrointestinal dysmotility (any) 31 74%
Gastroesophageal reflux disease and/or chronic
nausea
23 55%
Colonic (irritable bowel syndrome,
constipation, diarrhea)
17 40%
Other functional or autonomic-related
conditions (any)
24 57%
Abnormal heart rate 11 26%
Abnormal temperature regulation 7 17%
Dizziness 6 14%
Tinnitus 5 12%
Mental health disorders (any) 13 31%
Depression 10 24%
All cognitive disorders (any, including attention
deficit)
15 36%
Mental retardation or learning disabilities 13 31%
Autistic spectrum disorder 4 10%
Other conditions
Any neuromuscular disorder (non cognitive) 18 43%
Chronic fatigue or exercise intolerance 23 55%
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dizziness in the other) did not limit treatment. One par-
ticipant discontinued co-enzyme Q10 because of a pseu-
doporphyria rash. Such an association has not been
reported, and the rash did not reappear on treatment
with another brand of co-enzyme Q10. Cyproheptadine
caused lethargy in one participant, and two had vague
non-specific sensations while on multiple medications
both related and unrelated to this study.
Urine ketosis was noted in the medical record as posi-
tive in 20 out of 20 cases tested during vomiting epi-
sodes. Ketosis was not seen at baseline.
Discussion
This case series demonstrates excellent efficacy of cofac-
tor therapy (co-enzyme Q10, L-carnitine) combined
with amitriptyline. Treatment responses were subopti-
mal in only four cases, three of which could not tolerate
adequate dosages of amitriptyline, and never achieved a
“therapeutic” blood level (> 80 ng/ml of amitriptyline +
nortriptyline). With the removal of the fourth case of
the infant with multiple gastrointestinal malformations,
substantial efficacy (> 75% response) of this protocol in
children and youth > age 5 years was 19/22 at the onset
of treatment, and 19/19 in participants able to tolerate
amitriptyline. In the author’s observations, making treat-
ment decisions contingent of the blood levels of co-
enzyme Q10, carnitine and amitriptyline was very help-
ful in many cases, as children with sub-optimal clinical
improvement always demonstrated a low level of at least
one of the three agents, and increased dosing was asso-
ciated with the resolution of episodes. In order to
achieve these “therapeutic” blood levels and clinical effi-
cacy, some subjects required higher-than-customary
dosages, including up to 25 mg/kg/day (800 mg a day in
larger subjects) of co-enzyme Q10 and 2 mg/kg/day of
amitripyline. These dosages were well tolerated.
In participants under age five years, efficacy appears to
be good when cofactor therapy is combined with cypro-
heptadine, although the number of cases reported here is
small. Drug treatment varied by age in the present study
and in the NASPGHAN recommendations due to expert
opinion regarding low tolerability (tachycardia and
increased frustration) of amitriptyline in younger children
and low efficacy of cyproheptadine in older children [1].
Combining the 22 cases > age 5 years and 4 cases < 5
years, overall substantial efficacy (> 75% response) of
this protocol was 23/26 at the start of treatment, and
23/23 of those who could tolerate the regiment.
Clinical [11] and molecular [12] data suggest that CVS
in adults, in particular with the adult onset of vomiting
episodes [12] is distinct in many ways than CVS in chil-
dren. However, among the five adult cases with outcome
data in the present study, all of which had the adoles-
cent onset of vomiting episodes, two did not tolerate
a m i t r i p t y l i n e( s e ef o o t n o t e5i nT a b l e2 )a n di nt h e
three others episodes resolved (two with all three agents,
one with amitriptyline alone). Thus, there is inadequate
data in this generally-young cohort to suggest alternative
management based on adult age, although there may be
a higher rate of intolerance to amitriptyline in adults
than in children over age 5.
The major limitation on this study is that the participants
were treated on the basis of best available clinical therapy,
not on a prospective clinical trial. The protocol was used as
guidelines, not on a rigorous basis. For example, partici-
pants with severe disease (multiple hospitalizations) were
often treated simultaneously with cofactors and medication
(amitriptyline or cyproheptadine) at the first visit based on
the authors’ experience of frequent treatment failures on
Table 2 Response to treatment in 30 cases with cyclic vomiting syndrome
Amitriptyline Cyproheptadine Coenzyme Q10 L-carnitine Outcome:
Episodes
Resolved
Outcome:
Episodes >
75%
Improvement
Outcome:
Episodes >
50%
Improvement
Outcome:
Treatment
Failure
++ 3 3
a
+1 1
b
++ 3
c
++ 2
d
++ + 1 0 1
b 2
b
+1
++ 1
++ 1
++ + 1
a All 3 families elected not to treat with amitriptyline despite symptoms
bSee text
cIn one of those cases, amitriptyline was not tolerated, yet episodes resolved on topiramate + co-enzyme Q10
dIn one of those cases, episodes returned years later, then resolved on topiramate, while still on carnitine.
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were always given a trial of cofactors alone. Some families
started the therapies sequentially, and once episodes
stopped or greatly diminished would elect not to treat with
agents not yet attempted. A few families declined co-
enzyme Q10 therapy due to costs, which unlike all the
other therapies in this report was rarely covered by insur-
ance. A small number of participants were referred to the
author with partial efficacy on amitriptyline or cyprohepta-
dine, and when episodes resolved after increasing the
dosage the families chose not to start one or both cofactors.
These factors contributed to the complexity of the medical
regiments as listed in Table 2. However this limitation does
not diminish the observations herein of very-high efficacy
in general using these agents in clinical practice, either
alone or in combination.
The participants in this study include cases diagnosed by
the author in a primary care-like setting, tertiary care cases
referred by local pediatricians and gastroenterologists, and
quaternary care cases from other states that failed multiple
previous attempts at therapy. Since most participants were
ascertained in the latter two situations, the present cohort
is a sicker, more-treatment-resistant population of CVS
than is likely to be encountered by all but a few practi-
tioners. Since the more mildly-affected participants often
responded well to cofactor therapy alone, and that the side
effects of the cofactors are generally much less than that
of the medications [5 and author’s experience], a trial of
cofactor and dietary therapy alone may be warranted in
most CVS patients encountered in clinical practice, with
amitripyline or cyproheptidine added in refractory cases.
Many participants discontinued therapy at some point,
and in most the episodes returned, later resolving again on
renewed therapy. In the exceptional cases, vomiting epi-
sodes evolved into migraine headache, often at the time of
puberty, and the same protocol was used successfully in
migraine prophylaxis. No participants are known to be off
therapy and without both vomiting episodes and migraine
in the medium-term follow-up period of this study.
Conclusions
CVS is a disabling, common and difficult-to-treat condi-
tion. Our data suggest that a protocol consisting of mito-
chondrial-targeted cofactors (co-enzyme Q10 and L-
carnitine) plus amitriptyline (or possibly cyproheptadine
in preschoolers) coupled with fasting avoidance and
blood level monitoring is highly effective in the preven-
tion of vomiting episodes. A prospective blinded clinical
trial is needed. However, given the suggestion of efficacy
and excellent tolerability, health care providers may want
to consider combining these cofactors as a low-risk ther-
apeutic option along with the NASPGHAN recommen-
dations of amitriptyline (> 5 years) or cyproheptadine (<
5 years). A trial first of cofactors and fasting avoidance
alone may be warranted in cases without a history of
multiple hospitalizations for vomiting episodes.
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